Q-omics provides the consensus-scored KRTAP26-1 profile across patient tissues and cancer cell-line models. KRTAP26-1 expression is associated with patient survival in 10 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, KRTAP26-1 is differentially expressed in 1, with the highest sampling consensus in KICH. Additionally, KRTAP26-1 RNA expression shows 6,230 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight LIHC, KICH, and STAD as cancer lineages where KRTAP26-1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KRTAP26-1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KRTAP26-1 survival associations across molecular data types. KRTAP26-1 RNA expression shows survival associations in the most cancer types (10), followed by mutation status (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KRTAP26-1 RNA expression–survival associations across cancer types. High KRTAP26-1 expression shows unfavorable associations in LIHC, THYM, SCLC, BRCA and OV, but favorable associations in KIRC. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for KRTAP26-1 RNA expression.
This table summarizes KRTAP26-1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for KRTAP26-1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KRTAP26-1 shows higher tumor expression in KICH. The KICH box plot shows higher KRTAP26-1 RNA expression in tumor versus normal tissue (log2 FC = +0.044, t-test p = .018).
This table shows molecular features associated with KRTAP26-1 in patient tissues and cancer cell lines. In patient samples, KRTAP26-1 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set. In cancer cell lines, KRTAP26-1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in OVARY and LARGE_INTESTINE.
